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Aim To implement molecular analysis in the clinical di-
agnosis and management of Lynch syndrome (LS).
Methods We analyzed the mutations in MLH1 and MSH2 
in the selected LS families from the Republic of Mace-
donia.
Results We performed the very first genetic identifica-
tion of LS families and characterized a novel mutation. 
The novel nonsense germline point mutation c.392C>G 
in the codon 131 of MLH1(S131X) was identified as the 
underlying genetic cause of LS in three families. The hap-
lotype analysis suggested a founder effect of this muta-
tion in our population.
Conclusion We expect to detect the mutation in oth-
er LS patients from the region, and recommend cost-
effective screening for this mutation by restriction frag-
ment length polymorphism-polymerase chain reaction 
or DNA sequencing of MLH1 Exon5 prior to full genetic 
testing in all LS suspects of Macedonian ancestry.
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Lynch syndrome (LS), formerly known as hereditary non-
polyposis colorectal cancer, is considered the most com-
mon form of hereditary colorectal cancer (1). It is an au-
tosomal dominantly inherited predisposition to early 
development of colorectal cancers (CRC), as well as ma-
lignancies affecting the endometrium, ovaries, stomach, 
small intestine, hepatobiliary, and urinary tracts. The ge-
netic foundation of this syndrome in 50%-70% of cases are 
germline mutations in the mismatch repair (MMR) genes, 
leading to microsatellite instability (MSI) in the affected tis-
sue as a molecular hallmark of the disease. Germline mu-
tations in MLH1 and MSH2 account for 90% of these muta-
tions, but there is evidence for the involvement of PMS2 
and MSH6 (2-8).
The risk of colon cancer development in a patient with LS 
before the age of 70 is 52%-82%, ie, 9.5-15 times higher 
than in the general population (9). Genetic identification of 
a patient with LS alerts relatives to cancer risk and enables 
subsequent genetic testing, with a great benefit in terms 
of timing, expense, and effectiveness of surveillance (10), 
early detection of polyps, and reduction of cancer mortal-
ity. Furthermore, it spares the “healthy” relatives from un-
necessary fear and intensified surveillance. Therefore, the 
evaluation of inherited susceptibility to colorectal cancer 
is becoming a very common diagnostic and even prog-
nostic tool in colorectal cancer management. Up to now, 
there have been no official published data on the Lynch 
Syndrome and genetic testing for familial colorectal cancer 
predisposition in the Republic of Macedonia. In this regard, 
our aim was to implement molecular analyses in the clini-
cal diagnosis and management of the LS in the country.
MATeriAls AnD MeTHoDs
This is an ongoing prospective study investigating heredi-
tary colorectal cancer in the Republic of Macedonia. DNA 
was isolated using Proteinase K digestion/phenol/chloro-
phorm extraction (11) from fresh tumor tissue and periph-
eral blood of patients undergoing colon and/or rectum 
resection at the University Clinic for Digestive Surgery in 
Skopje. All participants provided informed consent. The re-
search protocol was approved by the Ethics Committee of 
the Faculty of Pharmacy in Skopje. It included screening 
for MSI in all tumor tissues, testing for BRAFV600E mutation 
and promoter hypermethylation of MMR genes in micro-
satellite instable cancers, followed by germline MMR test-
ing of patients fulfilling Amsterdam II criteria (12) (CRC or 
LS-related cancers in three or more relatives, one of whom 
was a first relative to the other two, the cancer was diag-
nosed in two or more successive generations, at least one 
of the cases was diagnosed before 50 years, the tumors 
had to be pathohystologically verified and familial ade-
nomatous polyposis excluded) or revised Bethesda crite-
ria (13) for LS (CRC diagnosed before the age of 50 years, 
or presence of synchronous, metachronous CRCs or other 
LS-associated tumors regardless of age, or CRC with the 
MSI-high histology diagnosed in a patient younger than 
60 years, or CRC diagnosed in a patient with one or more 
first-degree relatives with an LS-related tumor and at least 
one of whom was diagnosed under age of 50 years, or CRC 
diagnosed in two or more first or second degree relatives 
with LS-related tumor, regardless of age).
Paired tumor and blood DNA were used for the evalua-
tion of microsatellite instability applying fluorescent mul-
tiplex polymerase chain recation (PCR) of five mono- and 
dinucleotide markers: BAT25, BAT26, D2S123, D5S346, and 
D17S250, recommended by the National Cancer Institute 
(14). PCR-amplified fragments were separated with a cap-
illary gel electrophoresis on AbiPrism310 (Applied Biosys-
tems, Foster City, CA, USA) and a fragment analysis was 
performed using GeneMapper Software version 4.0.
Multiplex ligation-dependent probe amplification (MLPA) 
analysis with reagent kits from MRC-Holland (Amsterdam, 
the Netherlands), based on the technique described by 
Schouten et al (15) was performed for the detection of large 
genomic rearrangements in MLH1, MSH2, MSH6, and PMS2. 
Methylation-specific MLPA (MS-MLPA) analysis was done 
with ME011 reagent kit from the same manufacturer for the 
evaluation of tumor promoter methylation of MMR genes 
according to the recommendations by Perez-Carbonell (16).
Bi-directional DNA sequencing for the detection of point 
mutations, small deletions/duplications in MLH1 and 
MSH2, as well as detection of BRAFV600E mutation, was 
performed using BigDye Terminator v1.1 Cycle Sequenc-
ing Kit reagents (Applied Biosystems) followed by a capil-
lary gel electrophoresis and sequence analysis on AbiPrism 
310 genetic analyzer using Sequencing Analysis 5.3.1 com-
puter software (Applied Biosystems).
The haplotype analysis of chromosome 3p was performed 
on the two probands (index patients), by fragment analysis 
using fluorescent PCR/capillary gel electrophoresis with 
four highly polymorphic microsatellite markers: D3S1611, 
D3S1260, D3S1561, D3S1266 (17). This fragment analy-
sis was also performed on tumor DNA samples of the 
probands to evaluate the loss of heterozigosity. A 
SHORT COMMUNICATION498 Croat Med J. 2012;53:496-501
www.cmj.hr
restriction fragment length polymorphism-polymerase 
chain reaction (RFLP-PCR) assay previously described for 
the detection of the neighbor mutation D132H (18) was 
employed in screening for the mutation c.392C>G among 
CRC patients and the control group. Primer sequences and 
cycling conditions for all of the above PCR reactions are 
available upon request.
resulTs
The algorithm for the detection of MMR-defects employed 
in our study was based on MSI-screening of all colorectal 
cancers regardless of the family history and age at diagno-
sis, which has already been proven as a cost-effective ap-
proach for identifying individuals at risk of LS (19), with a 
93% sensitivity of identifying tumors arising from germline 
MMR mutation (20). This type of genetic instability was iden-
tified in 11% (44/389) of the colorectal cancers, selecting 
them for further genetic evaluation for LS. As tumor MLH1 
promoter methylation and BRAFV600E mutation are prov-
en predictors of a negative MMR mutation status (21-24), 
we evaluated their status in all microsatellite-instable can-
cers prior to germline analysis of MMR genes. Using these 
selection criteria we excluded 26 (59%) patients from futher 
analysis due to either the presence of the BRAFV600E muta-
tion (5 patients) or hypermethylation of the MLH1 promoter 
(21 patients). Finally, 8 patients fulfilling the Amsterdam II or 
revised Bethesda criteria (12,13) and whose tumors had MSI 
but lacked both BRAFV600E mutation and MMR genes pro-
moter hypermethylation were selected for laboratory de-
tection of germline MMR defects.
Following this algorithm, we identified the nonsense point 
mutation c.392C>G in two patients from different families. 
Pedigree charts present the patients’ characteristics and 
show the presence of colorectal cancer in at least two con-
secutive generations in both families (Figure 1). One of the 
probands was a woman diagnosed with cancer staged IIa 
of the transversal colon and a synchronous cancer of the 
stomach at the age of 49. She had also been diagnosed 
with endometrial cancer five years before. Her deceased 
mother and her uncle had also been diagnosed with early 
onset CRC. The other proband was a man diagnosed with 
metasynchronous cancers of the transversal and rectosig-
moidal colon at the age of 55. His mother, father, uncle, 
and sister had previously been diagnosed with CRC.
The initial screening for MMR deficiency by MSI testing 
identified high microstelite instability in the cancers of 
both probands, and further analysis revealed the ab-
sence of BRAFV600E mutation and MMR promoter hyperm-
ethylation. Since no large germline deletions or duplications 
in MLH1, MSH2, MSH6, and PMS2 were detected with the 
MLPA analysis, blood DNA samples were subjected to the 
bi-directional DNA sequencing analysis of the 19 MLH1- and 
16 MSH2- exons and flanking regions. The germline point 
mutation c.392C>G (Figure 2A) was identified in codon 131 
of MLH1 Exon5. The mutation c.392C>G (S131X) caused 
conversion of the TCA triplet encoding serine to TGA (UGA 
in RNA), which is a termination codon causing premature 
end of translation and synthesis of a truncated MLH1 pro-
tein consisting of 130 instead of 756 aminoacids (Figure 2B). 
This mutation can also be detected with a modification of a 
previously described PCRRFLP test for the detection of the 
neighboring D132H mutation. Furthermore, we detected 
the loss of heterozigosity on chromosome 3p, indicating the 
loss of the normal allele as the second event of the carcino-
genesis in these patients, in accordance with the Knudson’s 
two-hit hypothesis for cancer development (25). The result-
ing impaired function of MLH1 is held responsible for the 
mismatch repair deficiency leading to the development of 
colorectal cancer with microsatellite instability.
As the probands were not aware of their close common an-
cestry, we performed a haplotype analysis to evaluate this 
in more details. The haplotype similarity observed between 
the two index patients (Table 1) suggested that both pa-
tients were descendants of a common ancestor, founder 
of the c.392C>G mutation but they had either insufficient 
knowledge of their family trees or the mutation was rather 
old in the Macedonian population with a possible founder 
effect. According to these findings, it was understandable 
to expect identification of the mutation in other LS patients 
Figure 1. Pedigrees of the two families with lynch syndrome.
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with Macedonian ancestry and therefore we recommend 
the initial PCR/RFLP testing or MLH1Exon 5 sequencing pri-
or to the expensive, full genetic testing in all LS suspects 
originating from the Republic of Macedonia. Using this ap-
proach, we recently detected the same mutation in a third 
CRC family also without information on close familial rela-
tionship with the two previously detected LS families. This 
finding additionally supports our hypothesis of the founder 
effect of this mutation in the Macedonian population and 
justifies the recommendations for the initial screening.
Discussion
It is widely documented that colorectal cancer is a ma-
jor health burden, being the third most frequent type of 
cancer worldwide, with estimated annual incidence and 
mortality for 2008 of 1.2 and 0.6 million cases respective-
ly (27). The extended lifespan and the anticipated growth 
and aging of the human population are expected to in-
crease the number of people with a cancer history in the 
following years (28). The official CRC-statistics for the Re-
public of Macedonia are somewhat lower, probably most-
ly due to misreporting of the cause of death and lack of 
a unique national register of patients diagnosed with this 
type of malignancy. The situation is even worse regarding 
the hereditary syndromes, and until recently diagnosing of 
familial colorectal cancer was based exclusively on clinical 
findings and familial history of CRC. Our efforts in estab-
lishing and implementing molecular analyses in the clini-
cal diagnosis and management of the disease resulted in 
the first genetic identification of LS families in the country 
and enabled the implementation of family members’ ge-
netic counseling.
Our search through The Human Gene Mutation Data-
base (29) revealed that the mutation detected in our 
patients (c.392C>G) had not previously been identified 
and reported in other populations. Kurzawski et al (30) 
have reported a mutation in codon 131 with the same 
consequence on the protein level S131X, but with a dif-
ferent change in the DNA sequence (c. 392C>A).The ge-
netic analysis of other LS suspects is under way and up to 
now two additional MMR defects have been identified: a 
deletion spanning exons 3-12 of MLH1 in a 16-year-old 
boy by MLPA analysis and a IVS14-19A>G mutation in an-
other patient by DNA sequencing of MLH1, which should 
be functionally analyzed to confirm its involvement in LS. 
We expect that the results from this study will encour-
age the establishment of fortified screening programs in 
the country and region, combining clinicopathological 
and molecular approaches for identifying families with 
hereditary CRC syndromes and the underlying genetic 
cause, as essential steps toward improved prevention of 
cancer development and reduction of mortality in these 
families.
TABle 1. Haplotypes of the two index patients with the recurring mutation on chromosome 3p. All four of the evaluated microsatel-
lite markers spanning a DnA-region of approximately 10Mb, are present in the genomes of both patients in the same form (length) 










Patient 1 260 bp/262 bp†‡ 254 bp/254 bp 234 bp/240 bp 289 bp/293 bp
Patient 2 260 bp/262 bp 254 bp/258 bp 240 bp/242 bp 293 bp/297 bp
*Position within Homo sapiens chromosome 3 alternate assembly Huref whole genome shotgun sequence; according to the unisTs database (26).
†The bolded values denote the common alleles in both patients and point to the mutual haplotype associated with the identified genetic defect.
‡Base pairs (bp).
Figure 2. The novel c.392c>g (s131X) mutation underlies 
the impaired function of MLH1 detected by microsatellite 
instability in both lynch syndrome patients. (A) Detection of c. 
392c>g mutation by DnA sequencing. (B) The c>g conversion 
turns the wildtype (WT) 131st triplet coding for serine into the 
TgA (ugA in rnA) termination codon, causing premature end 
of translation and synthesis of a MlH1 product, which is 626 
aminoacids shorter than the wild type protein.
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One of the index patients had previously been diagnosed 
with endometrial cancer, but no genetic tests for heredi-
tary syndromes had been performed. Consequently, the 
LS had not been diagnosed at that point despite the clini-
cal findings and family history of colon cancer. This diag-
nostic failure may have contributed to the development of 
the subsequent stomach and colon cancers, which might 
have been prevented or at least detected in an earlier stage 
utilizing regular surveillance programs for LS patients. This 
fact emphasizes the necessity of employing genetic tests 
in risk assessment for LS in patients with CRC as well as 
all malignancies related to this syndrome fulfilling the Am-
sterdam II (12) or revised Bethesda criteria (13).
In conclusion, the very first molecular identification of LS 
in the Republic of Macedonia revealed a novel mutation in 
MLH1, as a genetic cause for this syndrome in three fami-
lies unaware of a close common ancestry. Suspecting the 
founder effect of this mutation, we recommend a routine 
screening by applying a RFLP-PCR test or DNA sequencing 
of MLH1 Exon5, as a cost-effective initial step in the genetic 
testing of all LS suspects with Macedonian ancestry.
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